Omalizumab antibody | AbD20669_hIgG1

100% Secure


Human anti Omalizumab:HRP

Anti-omalizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in full IgG1 format; it is ideal for bioanalytical assays for omalizumab and biosimilars. It is suitable as detection antibody in PK bridging ELISA with HCA236 to detect free drug, and as an ADA assay reference standard.

Human anti Omalizumab

Anti-omalizumab antibody is a recombinant, neutralizing anti-idiotypic antibody in full IgG1 format; it is ideal for bioanalytical assays for omalizumab and biosimilars. It is suitable as detection antibody in PK bridging ELISA with HCA236 to detect free drug, and as an ADA assay reference standard.

Product Type
Monoclonal Antibody
Clone
AbD20669_hIgG1
Isotype
IgG1
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
HCA235P E 0.1 mg
HCA235G E 1 mg
HCA235 E 0.1 mg
Human Anti-Omalizumab Antibody, clone AbD20669_hIgG1 is a paratope specific, anti-idiotypic antibody that binds specifically to omalizumab but not to free IgE or the drug/immunoglobulin complex. The antibody can be used to measure the levels of omalizumab and biosimilar products in bioanalytical assays.

Clone AbD20669_hIgG1 can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, HRP-conjugated and in full immunoglobulin (Ig) format, is recommended as the detection antibody, paired with the antibody in monovalent Fab format, clone AbD20669 (HCA236), as the capture antibody. The antibody in Ig format can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.

Omalizumab (brand name Xolair) is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma who have demonstrated a positive allergy skin test and whose symptoms are not controlled by inhaled corticosteroids.

Allergic asthma is mediated by IgE released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (FcεRI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human immunoglobulin E (IgE). By binding to circulating IgE at the site of FcεRI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release. Treatment with omalizumab has also been demonstrated to reduce the expression of FcεRI on mast cells and basophils, providing additional clinical benefit.

View a summary of all Anti-Omalizumab Antibodies

Product Details

Product Form
Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. Conjugated to horseradish peroxidase (HRP) - liquid.
Product Form
Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Preparation
Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.01% Thiomersal
Preservative Stabilisers
0.01% Thiomersal
Immunogen
Omalizumab
Affinity
The monovalent intrinsic affinity of this antibody was measured as KD = 1.1 nM by real time, label free molecular interaction analysis on immobilized omalizumab.
Approx. Protein Concentrations
IgG concentration 0.1 mg/ml
Approx. Protein Concentrations
Pack Size: 1 mg
IgG concentration 1.0 mg/ml
Pack Size: 0.1 mg
IgG concentration 0.5 mg/ml

Storage Information

Storage
Store at -70oC.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody.
Storage
Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life
12 months from date of despatch
Shelf Life
12 months from date of despatch

More Information

Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Acknowledgements
Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.

Xolair® is a registered trademark of Novartis.
Licensed Use
For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory
For research purposes only

Applications of Omalizumab antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
ELISA
ELISA
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
Technical Advice
Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
ELISA
This product may be used in direct ELISA and as a detection reagent in PK bridging assay together with HCA236 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
ELISA
This product may be used as bridging reagent in ADA assay development or, following HRP-conjugation, as a detection reagent in PK assay development together with HCA236 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug
Protocol: ADA bridging ELISA

Useful Reagents Available

Description Product Code Pack Size Applications List Price Quantity
Hispec Assay Diluent BUF049A 50 ml E IY
Recombinant Human IgE Lambda HCA171 0.1 mg E
Recombinant Human IgE Kappa HCA190 0.1 mg E
Human anti Omalizumab HCA236 0.1 mg E
Human anti Omalizumab (Drug/Target Complex) HCA237 0.1 mg E
Human anti Omalizumab (Drug/Target Complex) HCA238 0.1 mg E
Hispec Assay Diluent BUF049A 50 ml E IY
Recombinant Human IgE Lambda HCA171 0.1 mg E
Recombinant Human IgE Kappa HCA190 0.1 mg E
Human anti Omalizumab HCA236 0.1 mg E
Human anti Omalizumab (Drug/Target Complex) HCA237 0.1 mg E
Human anti Omalizumab (Drug/Target Complex) HCA238 0.1 mg E
LYNX Rapid HRP Antibody Conjugation Kit LNK002P 3 Conjugations For 400µg Antibody CJ

Product Specific References

References for Omalizumab antibody

  1. Kashiwagi, N. et al. (2017) Method for measuring anti-drug antibody
    US Patent application US20170315118A1